1002 related articles for article (PubMed ID: 17505496)
1. Personalized medicine: elusive dream or imminent reality?
Lesko LJ
Clin Pharmacol Ther; 2007 Jun; 81(6):807-16. PubMed ID: 17505496
[TBL] [Abstract][Full Text] [Related]
2. Personalized medicine.
Jain KK
Curr Opin Mol Ther; 2002 Dec; 4(6):548-58. PubMed ID: 12596356
[TBL] [Abstract][Full Text] [Related]
3. "Personalized medicine: elusive dream or imminent reality?": A commentary.
Roses A
Clin Pharmacol Ther; 2007 Jun; 81(6):801-5. PubMed ID: 17505494
[TBL] [Abstract][Full Text] [Related]
4. Assessing patient readiness for the clinical adoption of personalized medicine.
Issa AM; Tufail W; Hutchinson J; Tenorio J; Baliga MP
Public Health Genomics; 2009; 12(3):163-9. PubMed ID: 19204419
[TBL] [Abstract][Full Text] [Related]
5. The integration of molecular diagnostics with therapeutics. Implications for drug development and pathology practice.
Ross JS; Ginsburg GS
Am J Clin Pathol; 2003 Jan; 119(1):26-36. PubMed ID: 12520694
[TBL] [Abstract][Full Text] [Related]
6. The current status and future potential of personalized diagnostics: Streamlining a customized process.
Richmond TD
Biotechnol Annu Rev; 2008; 14():411-22. PubMed ID: 18606372
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the value of genomic diagnostics: implications for clinical practice and public policy.
Issa AM
Adv Health Econ Health Serv Res; 2008; 19():191-206. PubMed ID: 19548519
[TBL] [Abstract][Full Text] [Related]
8. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
9. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
10. Personalized medicine: challenges in assessing and capturing value in the commercial environment.
Ferrara J
Expert Rev Mol Diagn; 2006 Mar; 6(2):129-31. PubMed ID: 16512770
[No Abstract] [Full Text] [Related]
11. Personalized medicine: reality and reality checks.
Leeder JS; Spielberg SP
Ann Pharmacother; 2009 May; 43(5):963-6. PubMed ID: 19417116
[TBL] [Abstract][Full Text] [Related]
12. Improving the power of diagnostics in the era of targeted therapy and personalized healthcare.
Walk EE
Curr Opin Drug Discov Devel; 2010 Mar; 13(2):226-34. PubMed ID: 20205056
[TBL] [Abstract][Full Text] [Related]
13. [Companion diagnostics: significances and issues in its clinical application].
Miyachi H
Rinsho Byori; 2011 Jun; 59(6):602-9. PubMed ID: 21815484
[TBL] [Abstract][Full Text] [Related]
14. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
15. [Introductory remarks by chairpersons].
Kumagai S; Nobori T
Rinsho Byori; 2013 May; 61(5):419-20. PubMed ID: 23947181
[TBL] [Abstract][Full Text] [Related]
16. The prospects for "personalized medicine" in drug development and drug therapy.
Woodcock J
Clin Pharmacol Ther; 2007 Feb; 81(2):164-9. PubMed ID: 17259943
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers: a valuable tool in clinical research and medical practice.
Carini C
IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
[TBL] [Abstract][Full Text] [Related]
18. Implications of pharmacogenomics for drug development and clinical practice.
Ginsburg GS; Konstance RP; Allsbrook JS; Schulman KA
Arch Intern Med; 2005 Nov; 165(20):2331-6. PubMed ID: 16287761
[TBL] [Abstract][Full Text] [Related]
19. Challenge of personalized health care: to what extent is medicine already individualized and what are the future trends?
Fierz W
Med Sci Monit; 2004 May; 10(5):RA111-23. PubMed ID: 15114285
[TBL] [Abstract][Full Text] [Related]
20. The Affymetrix DMET platform and pharmacogenetics in drug development.
Deeken J
Curr Opin Mol Ther; 2009 Jun; 11(3):260-8. PubMed ID: 19479659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
